This study is for patients who are currently hospitalized with heart failure, a condition where the heart muscle is weakened and cannot pump blood effectively, and have low blood pressure. This study involves an investigational, not yet approved by the US Food and Drug Administration (FDA) intravenous (given into a vein) medication that is being studied to see if it can help increase blood pressure. The study involves a screening visit, randomization which is where either the study medication or placebo is assigned randomly, medication or placebo infusion for 24 hours, visits at day 2,3 and 4 and then a final visit at day 30.
Potential participants are people who have been on medications to treat heart failure, but you continue to have symptoms and qualify to have the FDA approved BAROSTIM NEO™ System implanted. The purpose of this research study is to describe the safety and effectiveness of the delivery system by an ultrasound guided implant procedure in people with heart failure. This is an experimental implant procedure where the data collected during and after procedure will help confirm the safety and effectiveness of the new implant procedure. This will be the first time humans will be implanted using this experimental procedure.
The purpose of this study is to evaluate the safety and effectiveness of ION-682884 and determine if it can help people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) which is a disease caused by change in a protein called transthyretin (TTR). ION-682884 is an investigational drug. "Investigational" means that ION-682884 is not yet approved for use in any settings outside of clinical research studies like this one and is considered experimental. ION-682884 has been shown to reduce the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in your blood may reduce the amount of amyloid deposits in your body and may keep your cardiomyopathy from getting worse over time. However, it is not known if ION-682884 will help your cardiomyopathy.
If you meet the requirements and agree to participate in this study, you will receive subcutaneous (under the skin) injections of either ION-682884 or placebo once every 4 weeks from week 1 through week 117.
Your participation in this study will last approximately 36 months and will consist of clinic visits and follow up visits at home.
This study is looking for volunteers who are having the Heart Mate 3 (HM3) Left Ventricular Assist Device (LVAD) implanted for treatment of heart failure. The study will collect medical information and patient experiences who have received treatment with the HM3. The traditional method to implant the HM3 is an incision in the middle of the chest through the breastbone (also called the sternum). This study will collect data if you have the Heartmate 3 implanted using a less invasive approach. Study participants will attend 8 visits over the course of 6 months.
The goal of this study is to find out if an investigational drug called ASP1128 (also called as MA-0217) is effective and safe as a treatment to prevent acute kidney injury (AKI) and/or reduce its severity in people who are at risk for AKI after heart surgery when compared to placebo (inactive substance). Researchers will look at how ASP1128 can act in the body.
Central sleep apnea occurs when the brain fails to send a signal to the muscles that control breathing during sleep causing brief pauses in breathing. It is widely believed that treatment of central sleep apnea may improve heart failure and quality of life. The goal of this study is to evaluate the effectiveness of oxygen treatment in patients with both central sleep apnea and heart failure.
The purpose of this study is to use an investigational device called the Atellica® VTLi™ test system to test a substance in your blood called troponin that may help with the diagnosis of a heart attack
This study is being done on patients who have heart failure, a condition where the heart muscle weakens and enlarges and cannot pump blood effectively. The purpose of this study is to assess the safety and effectiveness of a new device called the AccuCinch Ventricular Restoration System and compare it to treatment with standard heart failure medications alone. The AccuCinch Ventricular Restoration System consists of anchors, which attach to your heart muscle, sliders to connect the anchors and a thread like cord that goes through the anchors and is cinched to make your enlarged heart smaller so it can pump more efficiently. The device is implanted in one of the lower pumping chambers of the heart (called left ventricle). The study will have two groups, the treatment group in which participants undergo the device implant in addition to taking heart failure medications and the control group in which participants are treated with heart failure medications alone. Participation will last up to 5 years.
This study is collecting data on patients who are having an ablation procedure to correct an irregular heart beat called an arrhythmia. During this procedure an electrical map is made so your doctor can see where the irregular signals are located in your heart. The electrical mapping system called AcQMap®. After creating the electrical map your doctor will perform an ablation, which is a procedure where the irregular signals are burned with an ablation catheter. The catheter, a long, thin tube that enters at an artery in your groin area and is directed to your heart. The end of the catheter is able to burn tissue on contact. Your physician will use this catheter to burn the areas in your heart where the irregular heart beats start. This study will collect data from just before your ablation up to 3 years.